|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STOX1 |
Gene summary for STOX1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STOX1 | Gene ID | 219736 |
| Gene name | storkhead box 1 | |
| Gene Alias | C10orf24 | |
| Cytomap | 10q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000002 | UniProtAcc | Q6ZVD7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 219736 | STOX1 | LZE24T | Human | Esophagus | ESCC | 1.80e-03 | 1.72e-01 | 0.0596 |
| 219736 | STOX1 | P2T-E | Human | Esophagus | ESCC | 5.53e-63 | 1.20e+00 | 0.1177 |
| 219736 | STOX1 | P4T-E | Human | Esophagus | ESCC | 4.27e-09 | 2.36e-01 | 0.1323 |
| 219736 | STOX1 | P8T-E | Human | Esophagus | ESCC | 2.05e-07 | 1.69e-01 | 0.0889 |
| 219736 | STOX1 | P9T-E | Human | Esophagus | ESCC | 1.88e-05 | 1.63e-01 | 0.1131 |
| 219736 | STOX1 | P10T-E | Human | Esophagus | ESCC | 3.50e-02 | 6.19e-02 | 0.116 |
| 219736 | STOX1 | P12T-E | Human | Esophagus | ESCC | 9.44e-07 | 1.97e-01 | 0.1122 |
| 219736 | STOX1 | P20T-E | Human | Esophagus | ESCC | 8.24e-04 | 1.41e-01 | 0.1124 |
| 219736 | STOX1 | P26T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.06e-01 | 0.1276 |
| 219736 | STOX1 | P27T-E | Human | Esophagus | ESCC | 6.31e-57 | 1.13e+00 | 0.1055 |
| 219736 | STOX1 | P28T-E | Human | Esophagus | ESCC | 2.02e-06 | 1.61e-01 | 0.1149 |
| 219736 | STOX1 | P30T-E | Human | Esophagus | ESCC | 2.13e-03 | 1.56e-01 | 0.137 |
| 219736 | STOX1 | P39T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.70e-01 | 0.0894 |
| 219736 | STOX1 | P42T-E | Human | Esophagus | ESCC | 8.55e-05 | 2.21e-01 | 0.1175 |
| 219736 | STOX1 | P48T-E | Human | Esophagus | ESCC | 8.56e-12 | 2.38e-01 | 0.0959 |
| 219736 | STOX1 | P52T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.04e-01 | 0.1555 |
| 219736 | STOX1 | P57T-E | Human | Esophagus | ESCC | 9.35e-10 | 2.99e-01 | 0.0926 |
| 219736 | STOX1 | P62T-E | Human | Esophagus | ESCC | 2.57e-02 | 9.51e-02 | 0.1302 |
| 219736 | STOX1 | P128T-E | Human | Esophagus | ESCC | 1.37e-04 | 1.76e-01 | 0.1241 |
| 219736 | STOX1 | P130T-E | Human | Esophagus | ESCC | 7.52e-23 | 5.53e-01 | 0.1676 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
| GO:007145616 | Esophagus | ESCC | cellular response to hypoxia | 97/8552 | 151/18723 | 3.12e-06 | 3.51e-05 | 97 |
| GO:19019896 | Esophagus | ESCC | positive regulation of cell cycle phase transition | 77/8552 | 115/18723 | 3.20e-06 | 3.58e-05 | 77 |
| GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
| GO:00900689 | Esophagus | ESCC | positive regulation of cell cycle process | 142/8552 | 236/18723 | 4.79e-06 | 5.08e-05 | 142 |
| GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
| GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
| GO:00103891 | Esophagus | ESCC | regulation of G2/M transition of mitotic cell cycle | 64/8552 | 94/18723 | 9.21e-06 | 8.82e-05 | 64 |
| GO:006056210 | Esophagus | ESCC | epithelial tube morphogenesis | 187/8552 | 325/18723 | 9.95e-06 | 9.44e-05 | 187 |
| GO:19027491 | Esophagus | ESCC | regulation of cell cycle G2/M phase transition | 68/8552 | 102/18723 | 1.48e-05 | 1.33e-04 | 68 |
| GO:19019925 | Esophagus | ESCC | positive regulation of mitotic cell cycle phase transition | 62/8552 | 93/18723 | 3.47e-05 | 2.83e-04 | 62 |
| GO:00614184 | Esophagus | ESCC | regulation of transcription from RNA polymerase II promoter in response to hypoxia | 13/8552 | 13/18723 | 3.75e-05 | 3.04e-04 | 13 |
| GO:005188110 | Esophagus | ESCC | regulation of mitochondrial membrane potential | 51/8552 | 74/18723 | 4.42e-05 | 3.51e-04 | 51 |
| GO:19040312 | Esophagus | ESCC | positive regulation of cyclin-dependent protein kinase activity | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
| GO:005140912 | Esophagus | ESCC | response to nitrosative stress | 10/8552 | 10/18723 | 3.94e-04 | 2.26e-03 | 10 |
| GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
| GO:00485687 | Esophagus | ESCC | embryonic organ development | 228/8552 | 427/18723 | 7.28e-04 | 3.79e-03 | 228 |
| GO:00000021 | Esophagus | ESCC | mitochondrial genome maintenance | 17/8552 | 21/18723 | 1.03e-03 | 5.19e-03 | 17 |
| GO:19027511 | Esophagus | ESCC | positive regulation of cell cycle G2/M phase transition | 22/8552 | 30/18723 | 1.98e-03 | 8.90e-03 | 22 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STOX1 | SNV | Missense_Mutation | novel | c.1961C>G | p.Ser654Cys | p.S654C | Q6ZVD7 | protein_coding | tolerated(0.08) | possibly_damaging(0.817) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| STOX1 | SNV | Missense_Mutation | rs374535579 | c.953N>A | p.Arg318His | p.R318H | Q6ZVD7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| STOX1 | SNV | Missense_Mutation | c.2093N>T | p.Gly698Val | p.G698V | Q6ZVD7 | protein_coding | tolerated(0.19) | benign(0) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| STOX1 | SNV | Missense_Mutation | c.1030N>C | p.Val344Leu | p.V344L | Q6ZVD7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A24Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| STOX1 | SNV | Missense_Mutation | c.2779N>C | p.Glu927Gln | p.E927Q | Q6ZVD7 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| STOX1 | SNV | Missense_Mutation | c.1702N>T | p.Asp568Tyr | p.D568Y | Q6ZVD7 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| STOX1 | SNV | Missense_Mutation | rs770130603 | c.1508N>A | p.Arg503Gln | p.R503Q | Q6ZVD7 | protein_coding | deleterious(0.01) | benign(0.297) | TCGA-AA-3664-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STOX1 | SNV | Missense_Mutation | rs764960002 | c.1718N>A | p.Pro573His | p.P573H | Q6ZVD7 | protein_coding | deleterious(0.03) | possibly_damaging(0.65) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| STOX1 | SNV | Missense_Mutation | novel | c.2112G>T | p.Glu704Asp | p.E704D | Q6ZVD7 | protein_coding | tolerated(0.06) | benign(0.001) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| STOX1 | SNV | Missense_Mutation | novel | c.1606N>C | p.Ser536Pro | p.S536P | Q6ZVD7 | protein_coding | deleterious(0.01) | benign(0.042) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |